GlassScriptPhysician profile
Mckenzie Bonifield
NPI 1205411204
$1,144.51
in general payments reported to CMS, 2019-2025
21 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.46 · 2022: $89.92 · 2023: $287 · 2024: $218 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $230.81 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $162.42 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $151.67 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $87.54 | 2023-2024 | |
| Indivior INC. | $85.19 | 2025 | Sublocade |
| Glaxosmithkline, LLC. | $56.28 | 2025 | Shingrix, Arexvy, Penmenvy |
| Merck Sharp & Dohme LLC | $46.70 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Acadia Pharmaceuticals INC | $43.98 | 2025 | Daybue |
| Sanofi Pasteur INC. | $41.33 | 2024-2025 | |
| Amgen INC. | $37.24 | 2024 | Repatha, Otezla |
| Exact Sciences Corporation | $34.90 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $27.24 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.21 | 2025 | Caplyta |
| Pfizer INC. | $18.12 | 2025 | |
| Lilly USA, LLC | $17.36 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.59 | 2024 | Tradjenta, Jardiance |
| Phathom Pharmaceuticals, INC. | $14.22 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.73 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2025 | Zoryve |
| Axsome Therapeutics, INC. | $10.95 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Bonifield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.